Voya Investment Management LLC Purchases 128,432 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Voya Investment Management LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 827,138 shares of the pharmaceutical company’s stock after purchasing an additional 128,432 shares during the period. Voya Investment Management LLC’s holdings in Vertex Pharmaceuticals were worth $400,719,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of VRTX. United Services Automobile Association bought a new position in Vertex Pharmaceuticals during the 1st quarter valued at $2,933,000. Aries Wealth Management bought a new position in Vertex Pharmaceuticals during the 1st quarter valued at $293,000. Polar Asset Management Partners Inc. bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at $22,954,000. Brighton Jones LLC lifted its stake in Vertex Pharmaceuticals by 45.0% during the 1st quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company’s stock valued at $3,113,000 after acquiring an additional 1,994 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Vertex Pharmaceuticals by 25.1% during the 1st quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock valued at $2,425,000 after acquiring an additional 1,005 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $397.37 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The stock’s 50-day simple moving average is $423.87 and its 200 day simple moving average is $454.15. The stock has a market capitalization of $101.88 billion, a P/E ratio of 28.40 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same period in the previous year, the business posted ($12.83) EPS. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Morgan Stanley set a $439.00 target price on Vertex Pharmaceuticals and gave the stock an “equal weight” rating in a research note on Tuesday, August 5th. Guggenheim lowered their target price on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Erste Group Bank cut Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Royal Bank Of Canada lowered their target price on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 5th. Finally, Scotiabank lowered their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $496.05.

Insiders Place Their Bets

In related news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.